儿科药物 SCIE

期刊简介预计审稿时间： 12周，或约稿

Pediatric Drugs promotes the optimization and advancement of all aspects of pharmacotherapy for healthcare professionals interested in pediatric drug therapy (including vaccines). The program of review and original research articles provides healthcare decision makers with clinically applicable knowledge on issues relevant to drug therapy in all areas of neonatology and the care of children and adolescents. The Journal includes:

-overviews of contentious or emerging issues.

-comprehensive narrative reviews of topics relating to the effective and safe management of drug therapy through all stages of pediatric development.

-practical reviews covering optimum drug management of specific clinical situations.

-systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.

-Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in the pediatric population.

-original research articles reporting the results of well-designed studies with a strong link to clinical practice, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic and pharmacoepidemiological studies.

Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Pediatric Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.

《儿科药物》致力于为对儿科药物治疗（包括疫苗）感兴趣的医疗保健专业人士促进药物治疗各个方面的优化和进步。评论和原创研究文章计划为医疗保健决策者提供有关新生儿学和儿童及青少年护理所有领域药物治疗相关问题的临床适用知识。该期刊包括：

-有争议或新兴问题的概述。

-全面叙述与儿科发展各个阶段药物治疗的有效和安全管理有关的主题。

-实用评论，涵盖特定临床情况的最佳药物管理。

-系统评论，使用 PRISMA 声明概述的明确、系统方法，汇总经验证据以回答特定研究问题。

-Adis 药物评论，评论儿科人群中新药和成熟药物的特性和治疗地位。

-原创研究文章，报告精心设计的研究结果，与临床实践密切相关，例如临床药效学和药代动力学研究、临床试验、荟萃分析、结果研究以及药物经济学和药物流行病学研究。

其他数字功能（包括动画摘要、视频可以随文章发布摘要、幻灯片、音频幻灯片、教学视频、信息图表、播客和动画等内容；这些内容旨在提高期刊内容的知名度、读者群和教育价值。此外，在《儿科药物》上发表的文章可能会附有通俗易懂的摘要，以帮助对该领域有一定了解但不具备深入专业知识的读者了解重要的医学进展。

《Pediatric Drugs》(儿科药物)编辑部通讯方式为5 THE WAREHOUSE WAY, NORTHCOTE, NEW ZEALAND, AUCKLAND, 0627。如果您需要协助投稿或润稿服务，您可以咨询我们的客服老师。我们专注于期刊投稿服务十年，熟悉发表政策，可为您提供一对一投稿指导，避免您在投稿时频繁碰壁，节省您的宝贵时间，有效提升发表机率，确保SCI检索（检索不了全额退款）。我们视信誉为生命，多方面确保文章安全保密，在任何情况下都不会泄露您的个人信息或稿件内容。